Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus?

Canadian Journal of Gastroenterology

Volumn 24, Issue 2, 2010, Pages 121-125

  Narula, Neeraj ^a   Yamamura, Deborah L R ^b   Marshall, John K ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Crohn's disease; Immunization; Inflammatory bowel disease; Influenza; Ulcerative colitis; Vaccination

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; MESALAZINE; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ARTHRALGIA; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FEVER; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INJECTION SITE REACTION; MALAISE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY;

COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, INACTIVATED;

EID: 77950507081     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/375878     Document Type: Review

References (44)

1. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: A population-based study. Am J Gastroenterol 2006;101:1559-1568 (Pubitemid 43980630)
2. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 2007;369:1641-1657 (Pubitemid 46722637)
3. Toruner M, Loftus Jr EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-936 (Pubitemid 351451967)
4. Hutfless SM, Weng X, Liu L, et al. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007;133:1779-1786
5. Fiore AE, Shay DK, Broker K, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008;57:1-60.
6. Public Health Agency of Canada. Influenza (June 4, 2009). 〈http://www.phac-aspc.gc.ca/influenza/index-eng.php〉 (Version current at October 24, 2009).
7. Kangro HO, Chong SK, Hardiman A, et al. A prospective study of viral and mycoplasma infections in chronic inflammatory bowel disease. Gastroenterology 1990;98:549-553 (Pubitemid 20069688)
8. Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004;53:1-40.
9. Public Health Agency of Canada. Statement on Influenza Vaccination for the 2008-2009 season (July 15, 2008). 〈http://www.phac-aspc.gc.ca/publicat/ ccdr-rmtc/08vol34/acs-3/index-eng.php〉 (Version current at October 24, 2009).
10. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:677-692 (Pubitemid 39276481)
11. Rahier JF, Ben-Horin S, Chowers Y, et al; on behalf of the European Crohn's and Colitis Organisation (ECCO). European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. JCC 2009;3:47-91.
12. Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol 2009;333:43-82.
13. Public Health Agency of Canada. Statement on Seasonal Trivalent Inactivated Influenza Vaccine (TIV) for 2009-2010 (October 29, 2009) 〈http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/acsdcc-6/index-eng. php〉 (Version current at October 29, 2009).
14. Williams MS, Wood JM. A brief history of inactivated influenza virus vaccines. In: Options for the Control of Influenza II. Hannoun C, Kenda AP, Klenk HD, Ruben FL, eds. Amsterdam: Elsevier Science Publishers, 1993:169-171
15. Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:851-856 (Pubitemid 47031059)
16. Matsuzaki A, Suminoe A, Koga Y, et al. Immune response after influenza vaccination in children with cancer. Pediatr Blood Cancer 2005;45:831-837 (Pubitemid 41416495)
17. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006;101:1834-1840 (Pubitemid 44166594)
18. Sowden E, Mitchell WS. An audit of influenza and pneumococcal vaccination in rheumatology outpatients. BMC Musculoskelet Disor 2007;8:58. (Pubitemid 47252000)
19. Bridges MJ, Coady D, Kelly CA, et al. Factors influencing uptake of influenza vaccination in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:685. (Pubitemid 36760575)
20. Beyer WE, Palache AM, de Jong JC, et al. Cold-adapted live influenza vaccine versus inactivated vaccine: Systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002;20:1340-1353
21. Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009;104:444-453
22. Gelinck LB, van der Bijl AE, Beyer WE, et al. The effect of antitumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008;67:713-716
23. Candon S, Thervet E, Lebon P, et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant 2009;9:2346-2354
24. Grekas D, Alivanis P, Kiriazopoulou V, et al. Influenza vaccination on renal transplant patients is safe and serologically effective. Int J Clin Pharmacol Ther Toxicol 1993;31:553-556 (Pubitemid 2007653)
25. Kobashigawa JA,Warner-Stevenson L, Johnson BL, et al. Influenza vaccine does not cause rejection after cardiac transplantation. Transplant Proc 1993;25:2738-2739
26. Mauch TJ, Crouch NA, Freese DK, et al. Antibody response of pediatric solid organ transplant recipients to immunization against influenza virus. J Pediatr 1995;127:957-960
27. Briggs WA, Rozek RJ, Migdal SD, et al. Influenza vaccination in kidney transplant recipients: Cellular and humoral immune responses. Ann Intern Med 1980;92:471-477
28. Gross PA, Lee H, Wolff JA, et al. Influenza immunization in immunosuppressed children. J Pediatr 1978;92:30-35
29. Versluis DJ, Beyer WE, Masurel N, et al. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 1986;42:376-379
30. Burbach G, Bienzle U, Stark K, et al. Influenza vaccination in liver transplant recipients. Transplantation 1999;67:753-755
31. Lawal A, Basler C, Branch A, Gutierrez J, Schwartz M, Schiano TD. Influenza vaccination in orthotopic liver transplant recipients: Absence of post administration ALT elevation. Am J Transplant 2004;4:1805-1809
32. Kimball P, Verbeke S, Flattery M, Rhodes C, Tolman D. Influenza vaccination does not promote cellular or humoral activation among heart transplant recipients. Transplantation 2000;69:2449-2451
33. White-Williams C, Brown R, Kirklin J, et al. Improving clinical practice: Should we give influenza vaccinations to heart transplant patients? J Heart Lung Transplant 2006;25:320-323
34. Holvast B, Huckriede A, Kallenberg CG, et al. Influenza vaccination in systemic lupus erythematosus: Safe and protective? Autoimmun Rev 2007;6:300-305
35. Elkayam O. Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis. Clin Dev Immunol 2006;13:349-351
36. Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in rheumatoid arthritis patients: The effect of rituximab on the humoral response. Ann Rheum Dis 2008;67:937-941
37. Salemi S, Picchianti-Diamanti A, Germano V, et al. Influenza vaccine adminstration in rheumatoid arthritis patients under treatment with TNFalpha blockers: Safety and immunogencity. Clin Immunol 2009, Oct 20 [Epub ahead of print].
38. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007;34:272-279
39. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000;284:1655-1663
40. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979;110:105-123
41. Juurlink DN, Stukel TA, Kwong J, et al. Guillain-Barre syndrome after influenza vaccination in adults: A population-based study. Arch Intern Med 2006;166:2217-2221
42. Kaplan JE, Katona P, Hurtwitz ES, et al. Guillain-Barre syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination. JAMA 1982;248:698-700.
43. Kwan OS, Park YS, Choi JH, et al. A case of ulcerative colitis relapsed by influenza vaccination. Korean J Gastroenterol 2007;49:327-330
44. Fields SW, Baiocco PJ, Korelitz BI. Influenza vaccinations: Should they really be encouraged for IBD patients being treated with immunosuppressives? Inflamm Bowel Dis 2009;15:649-651